Adenosine A2A Receptor Antagonists and Parkinson's Disease: State of the Art and Future Directions

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|14|15|1475-1489

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.14, Iss.15, 2008-05, pp. : 1475-1489

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Novel therapy in Parkinson's disease: adenosine A2A receptor antagonists

By Szabóó Nikoletta   Kincses Zsigmond Tamáás   Véécsei Láászlóó  

Expert Opinion on Drug Metabolism and Toxicology, Vol. 7, Iss. 4, 2011-04 ,pp. : 441-455

Informa Healthcare

Access to resources Recommend Favorite

Adenosine A 2A receptor antagonists as new agents for the treatment of Parkinson's disease

By Richardson P.J.   Kase H.   Jenner P.G.  

Trends in Pharmacological Sciences, Vol. 18, Iss. 9, 1997-10 ,pp. : 338-344

Elsevier

Access to resources Recommend Favorite

Adenosine A2A Receptor Antagonists for Parkinson’s Disease: Rationale, Therapeutic Potential and Clinical Experience

By Hauser Robert A.  

Drugs & Aging, Vol. 22, Iss. 6, 2005-01 ,pp. : 471-482

Adis International

Access to resources Recommend Favorite

Istradefylline, a novel adenosine A2A receptor antagonist, for the treatment of Parkinson’s disease

By Jenner Peter  

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 6, 2005-06 ,pp. : 729-738

Informa Healthcare

Access to resources Recommend Favorite

Two new adenosine receptor antagonists for the treatment of Parkinson's disease: istradefylline versus tozadenant

By Perez-Lloret Santiago   Merello Marcelo  

Expert Opinion on Pharmacotherapy, Vol. 15, Iss. 8, 2014-06 ,pp. : 1097-1107

Informa Healthcare

Access to resources Recommend Favorite